Core Viewpoint - Fortrea, a leading global contract research organization, is set to present at the J.P. Morgan Annual Healthcare Conference on January 13, 2026, at 11:15 am PST, highlighting its role in the life sciences industry [1]. Company Overview - Fortrea (Nasdaq: FTRE) specializes in providing clinical development solutions to the life sciences sector, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to enhance healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over 30 years of experience across more than 20 therapeutic areas [3]. - Fortrea operates in approximately 100 countries, emphasizing a strong investigator site network and a commitment to delivering agile solutions to its clients [3].

DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference in January: J.P. Morgan Annual Healthcare Conference (San Francisco)Date:Tuesday, January 13, 2025Time:5:15 pm PSTFormat:Presentation and Q&A The live webcast and replay can be accessed through the “Events” section of Fortrea’s Inves ...

Core Insights - Fortrea, a leading global contract research organization (CRO), is actively participating in key healthcare conferences in December 2025, showcasing its commitment to engaging with investors and stakeholders [1][2]. Company Overview - Fortrea (Nasdaq: FTRE) provides clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to accelerate healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging over three decades of experience across more than 20 therapeutic areas [3]. - Fortrea operates in approximately 100 countries, emphasizing a diverse and talented team to deliver agile solutions globally [3].

Core Viewpoint - Fortrea has successfully completed a debt tender offer, purchasing $75,743,000 of its outstanding Senior Secured Notes, which is part of its strategy to optimize its capital structure and manage its financial resources effectively [1][2]. Group 1: Debt Tender Offer Details - The tender offer involved repurchasing a portion of the 7.500% Senior Secured Notes due 2030, reducing the outstanding principal from $570,000,000 to $494,257,000 [1]. - The total principal amount of Notes validly tendered exceeded $75,744,000, and the company accepted for purchase $75,743,000 based on a Final Proration Factor of 0.154199 [2]. Group 2: Financial Management and Strategy - The transaction was funded entirely with cash on hand, highlighting the strength of Fortrea's balance sheet and disciplined financial management [2]. - The completion of the tender offer aligns with the company's divestiture of its Fortrea Patient Access and Endpoint Clinical businesses, which was finalized in June 2024 [1]. Group 3: Company Overview - Fortrea is a leading global provider of clinical development solutions, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to drive healthcare innovation [3]. - The company offers a range of services including phase I-IV clinical trial management and consulting, leveraging over three decades of experience across more than 20 therapeutic areas [3].

Core Viewpoint - Fortrea has initiated a debt tender offer to purchase up to $75,744,000 in outstanding 7.500% Senior Secured Notes due 2030, primarily to comply with indenture provisions following a divestiture [1][2]. Group 1: Tender Offer Details - The tender offer is subject to the satisfaction or waiver of specific terms outlined in the Offer to Purchase dated October 20, 2025 [2]. - The tender offer will expire at 5:00 p.m. New York City time on November 18, 2025, unless extended or terminated [3]. - Each $1,000 principal amount of the Notes validly tendered will receive $1,000 in cash, plus accrued and unpaid interest from the last interest payment date to the settlement date [3][5]. Group 2: Conditions and Procedures - The tender offer is contingent upon the satisfaction or waiver of conditions described in the Offer to Purchase [6]. - Notes must be transferred to the Tender Agent through DTC's Automated Tender Offer Program for holders wishing to tender [4]. - If the total purchase price of validly tendered Notes exceeds the Maximum Amount, proration may occur [5]. Group 3: Company Overview - Fortrea is a leading global provider of clinical development solutions, partnering with biopharmaceutical, biotechnology, and medical device companies [9]. - The company offers services across various phases of clinical trials and has extensive experience in over 20 therapeutic areas [9][10].

Core Insights - Fortrea, a leading global contract research organization (CRO), will release its third quarter 2025 financial results on November 5, 2025, before market opens [1] - A conference call will be held at 8:00 am ET on the same day to discuss the financial results and conduct a Q&A session [1] Company Overview - Fortrea is a prominent provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [3] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over three decades of experience across more than 20 therapeutic areas [3] - Fortrea operates in approximately 100 countries, delivering focused and agile solutions to its global customers [3]

Core Viewpoint - Fortrea has appointed William Sharbaugh to its Board of Directors, bringing over three decades of experience in the pharmaceutical industry, which will enhance the company's leadership and strategic direction [2][3][4]. Company Overview - Fortrea (Nasdaq: FTRE) is a leading global contract research organization (CRO) that provides clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [5]. - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [5]. Leadership Appointment - William Sharbaugh's extensive background includes roles as chairman of the board of Ora LLC and board member of Launch Therapeutics, Inc., along with previous positions at PPD, Inc. and Bristol-Myers Squibb [4]. - Sharbaugh's experience in both CRO and pharmaceutical companies is expected to provide practical insights to Fortrea's Board, aligning with the company's mission to deliver life-changing treatments to patients [3][4]. Strategic Focus - The appointment of Sharbaugh is seen as a strategic move to enhance Fortrea's capabilities in drug development and to strengthen its position as a trusted partner to clients [3][4].

Core Insights - Fortrea reported a revenue of $710.3 million for Q2 2025, an increase from $662.4 million in Q2 2024, indicating a year-over-year growth of approximately 7.5% [4][21] - The company experienced a GAAP net loss of $(374.9) million in Q2 2025, which included a non-cash goodwill impairment charge of $309.1 million, compared to a net loss of $(99.3) million in Q2 2024 [5][21] - Adjusted net income for Q2 2025 was $17.6 million, with diluted earnings per share of $0.19, contrasting with an adjusted net loss of $(2.3) million and a diluted loss per share of $(0.03) in Q2 2024 [5][34] - The backlog as of June 30, 2025, was $7,547 million, with a book-to-bill ratio of 0.79x for the quarter [6][9] - The company raised its revenue guidance for the full year 2025 to a range of $2,600 million to $2,700 million, while affirming adjusted EBITDA guidance between $170 million and $200 million [11][9] Financial Performance - For the first half of 2025, Fortrea reported revenues of $1,361.6 million, up from $1,324.5 million in the first half of 2024 [7][21] - The GAAP net loss for the first half of 2025 was $(937.8) million, which included a non-cash goodwill impairment charge of $797.9 million, compared to a net loss of $(179.1) million in the first half of 2024 [8][21] - Adjusted EBITDA for Q2 2025 was $54.9 million, slightly down from $55.2 million in Q2 2024 [5][29] Leadership Transition - Anshul Thakral joined Fortrea as CEO on August 4, 2025, succeeding Interim CEO Peter M. Neupert, who remains chairman of the Board [2][3] - Thakral expressed confidence in the company's position to assist customers in navigating the development landscape and emphasized the value of the company's team and operational excellence [3][2] Operational Highlights - The company is on track with cost-saving initiatives, which are expected to enhance operational efficiency [9] - Fortrea's leadership is focused on creating value for customers, employees, and shareholders, as stated by CFO Jill McConnell [2][3]

Core Insights - Fortrea has appointed Tracy Krumme as the new senior vice president of investor relations, succeeding Hima Inguva, who is leaving for other career opportunities [1][2] - Krumme brings over 30 years of experience in investor relations and capital markets, with a strong background in the CRO, life sciences, and healthcare sectors [2][3] - The company aims to enhance its investor relations strategy and communicate its vision and value proposition effectively to the investment community [3] Company Overview - Fortrea is a leading global contract research organization (CRO) that provides clinical development solutions to the life sciences industry [3] - The company partners with biopharmaceutical, biotechnology, medical device, and diagnostic companies to accelerate healthcare innovation and deliver life-changing therapies [3] - Fortrea offers services including phase I-IV clinical trial management, clinical pharmacology, and consulting, leveraging three decades of experience across more than 20 therapeutic areas [3]

Core Points - Fortrea has granted employment inducement awards to Anshul Thakral, the newly appointed President and CEO, effective August 4, 2025 [1] - The awards include 1,250,000 performance share units (PSUs) and 1,250,000 restricted stock units (RSUs), with specific vesting conditions [2] - The grants were made under the Company's 2025 Inducement Award Plan and comply with Nasdaq Listing Rules [3] Company Overview - Fortrea is a leading global provider of clinical development solutions for the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [4] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [4] - Fortrea operates in approximately 100 countries, providing agile solutions to its global customers [4]